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Abstract Since 2004, cannabis has been prohibited by the
World Anti-Doping Agency for all sports competitions. In
the years since then, about half of all positive doping
cases in Switzerland have been related to cannabis
consumption. In doping urine analysis, the target analyte
is 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-
COOH), the cutoff being 15 ng/mL. However, the wide
urinary detection window of the long-term metabolite of
Δ9-tetrahydrocannabinol (THC) does not allow a conclu-
sion to be drawn regarding the time of consumption or the
impact on the physical performance. The purpose of the
present study on light cannabis smokers was to evaluate
target analytes with shorter urinary excretion times.
Twelve male volunteers smoked a cannabis cigarette
standardized to 70 mg THC per cigarette. Plasma and
urine were collected up to 8 h and 11 days, respectively.
Total THC, 11-hydroxy-Δ9-tetrahydrocannabinol (THC-
OH), and THC-COOH were determined after hydrolysis
followed by solid-phase extraction and gas chromatography/
mass spectrometry. The limits of quantitation were 0.1–
1.0 ng/mL. Eight puffs delivered a mean THC dose of
45 mg. Plasma levels of total THC, THC-OH, and THC-
COOH were measured in the ranges 0.2–59.1, 0.1–3.9, and
0.4–16.4 ng/mL, respectively. Peak concentrations were
observed at 5, 5–20, and 20–180 min. Urine levels were
measured in the ranges 0.1–1.3, 0.1–14.4, and 0.5–38.2 ng/
mL, peaking at 2, 2, and 6–24 h, respectively. The times of
the last detectable levels were 2–8, 6–96, and 48–120 h.
Besides high to very high THC-COOH levels (245±
1,111 ng/mL), THC (3±8 ng/mL) and THC-OH (51±
246 ng/mL) were found in 65 and 98% of cannabis-
positive athletes’ urine samples, respectively. In conclusion,
in addition to THC-COOH, the pharmacologically active
THC and THC-OH should be used as target analytes for
doping urine analysis. In the case of light cannabis use, this
may allow the estimation of more recent consumption,
probably influencing performance during competitions.
However, it is not possible to discriminate the intention of
cannabis use, i.e., for recreational or doping purposes.
Additionally, pharmacokinetic data of female volunteers are
needed to interpret cannabis-positive doping cases of female
athletes.
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Introduction
Before 2004, cannabis was only prohibited in competitions
in some sports. Since January 2004, the World Anti-Doping
Agency (WADA) has listed cannabis as a prohibited
substance for all sports, however in competitions only [1].
Antidoping Switzerland, the organization responsible for
antidoping measures in Switzerland, is bound to this list too
[2]. In addition, cannabinoids are classified as so-called
specified substances. Often athletes plausibly claim to have
consumed cannabis several days or even weeks before a
competition and only for recreational purposes not related
to the competition. Other reported reasons for use are, for
example, sleep improvement, stress reduction, and relaxa-
tion [3, 4]. Effects negatively influencing sport performance
are reduced reaction time, problems of motor and hand–eye
coordination, problems of perceptual accuracy, etc. [4].
Besides the ongoing increase of recreational cannabis use
and the easy accessibility of highly potent material, it is
also becoming increasingly popular to use cannabis
products in a therapeutic context, for example, in the form
of uncontrolled self-medication (cannabis tea, etc.) or as
prescribed drug (dronabinol) to treat pain, muscle spasms,
etc. This leads to an increased risk of positive doping urine
tests.
Consumption of Δ9-tetrahydrocannabinol (THC)-con-
taining cannabis products, such as marijuana (herbal
cannabis) and hashish (resinous cannabis), is controlled in
sports by testing urine samples. Urine concentrations of
15 ng/mL or more of 11-nor-9-carboxy- Δ9-tetrahydrocan-
nabinol (THC-COOH; the main THC metabolite, not
psychoactive [5, 6]) are considered as “cannabis-positive.”
This cutoff value of 15 ng/mL should avoid positive results
due to passive inhalation. In general, a high number of adverse
analytical findings for cannabis is reported by accredited
laboratories [7]. Since 2004, about half of all positive
doping cases in Switzerland have been related to cannabis
consumption [8]. It is unsatisfactory if the authorities have to
sanction athletes for cannabis use in a competition although
the consumption took place days or even weeks before and
was not intended to improve performance.
The high lipophilicity of THC, resulting in high tubular
reabsorption [9], is responsible for the low renal excretion
of the unchanged drug [9–11]. Body storage of THC
increases with increasing frequency and chronicity of
cannabis use [12]. Like its metabolites 11-hydroxy-Δ9-
tetrahydrocannabinol (THC-OH), which is psychoactive too
[13–16], and THC-COOH it undergoes phase II biotrans-
formation to a glucuronide conjugate [17]. About one third
of the absorbed dose is excreted in the urine, about two
thirds are eliminated via feces [18, 19]. Later it was
suggested that urinary THC concentrations of more than
2 ng/mL following enzymatic hydrolysis indicate cannabis
exposure within 8 h of specimen collection [20]. However,
sample collection lasted only for 8 h after controlled drug
administration. Recently it has been shown that after a user
has refrained from long-term heavy cannabis use, THC and
THC-OH are excreted in urine for up to 24 days [12]. It
was concluded that these cannabinoids are not suited as
biomarkers of recent cannabis exposure.
After single and frequent consumption (daily) THC-
COOH is detectable in urine for up to 3 and 30 days,
respectively. This wide detection window is mainly due to
multicompartment kinetics, multiphase distribution and
elimination, and high affinity for lipid tissue [21–23]. For
example, fatty acid conjugates of hydroxylated cannabi-
noids have been identified as long-retained metabolites [22,
24]. It is problematic to predict the time of drug use and the
degree of impairment of the physical and psychological
performance on the basis of urinary THC-COOH levels
[20]. Plasma levels are more reliable, whereas a urine test
positive for THC-COOH so far only allows a “yes”
conclusion and is not a proof of recent cannabis use [25,
26]. Consequently, it was the main objective of the present
study to evaluate target analytes with shorter urinary
excretion times. Pharmaceutical-grade cannabis cigarettes,
the most prevalent application form, were used for this
clinical trial on light cannabis users. Finally, urine samples
from athletes who tested cannabis-positive (15 ng/mL or
more THC-COOH) were reanalyzed.
Experimental
Materials
THC, THC-OH, THC-COOH and their d3-deuterated
analogs (internal standards) were supplied by Lipomed
(Arlesheim, Switzerland). β-Glucuronidase (type IX-A
from Escherichia coli) and N,O-bis(trimethylsilyl)trifluor-
oacetamide (BSTFA) containing 1% trimethylchlorosilane
(TMCS) were from Sigma-Aldrich (Buchs, Switzerland).
The Bakerbond C18 500 mg/3 mL and UCT Clean Screen
CSTHC203 200 mg/3 mL solid phase extraction (SPE)
columns were provided by Stehelin (Basel, Switzerland)
and Amchro (Hattersheim, Germany), respectively. Pooled
plasma was provided by the Blood Donation Center
Berne. All other chemicals were of the highest analytical
grade and were supplied by Sigma-Aldrich or Grogg
(Bern, Switzerland).
Clinical test preparation
Dried cannabis flowers (cannabis flos, variety Bedrocan)
standardized to 7% THC (Bedrobinol®) were supplied by
the Dutch Ministry of Health, Welfare & Sport, Office of
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Medicinal Cannabis (The Hague, The Netherlands). To
prepare the cigarettes, this material was then crushed,
homogenized, and 1,000 mg was filled into Cones®
(Vandenberg Special Products, Rotterdam, The Nether-
lands), resulting in a content of 70 mg THC.
Clinical study
Twelve healthy, male volunteers (age 26±3 years, BMI
24±2 kg/m2), tobacco and light cannabis smokers (once or
less per month), with normal lung functions (spirometry)
and a negative cannabis urine test (Instant-View marijuana/
THC urine test, Medim, Baar, Switzerland) before the start
of the session were included in the study (ClinicalTrials.gov
identifier NCT00534716). The use of alcohol, any medica-
tion, or drugs within the last 2 days prior to and during the
1-day session was not allowed. Cannabis use was also not
allowed during the following 10 days of urine collection.
All participants provided written informed consent and
were under medical surveillance at the Clinical Investiga-
tion Unit (CIU) of the University Hospital Berne for 10 h
after drug administration. To keep the subjects at the CIU
for the whole study period (11 days) was technically not
feasible. However, the subjects were evaluated very
carefully regarding reliability and potential risk of smoking
cannabis when not under observation. The study was
conducted according to GCP and ICH guidelines and
considering the Declaration of Helsinki (Washington). It
was approved by the Ethics Committee of the Canton of
Berne (permit KEK-BE 033/07), Swissmedic (reference no.
2007 DR 1139), and the Swiss Federal Office of Public
Health.
The standardized smoking and inhalation procedure was
performed according to a paced-puffing procedure [27, 28].
It consisted of eight inhalation cycles, with 20-s retention
and 40-s pause. According to the residual THC content, the
mean THC amount released was 45±7 mg per cigarette.
Blood samples (10 mL) were collected by a venous catheter
15 min before (baseline) and 5, 10, 20, 40, 60, 90, 120,
180, 240, and 480 min after smoking. The samples were
immediately centrifuged (1,500 rcf, 10 min, 4 °C) and the
plasma was then instantly frozen at −20 °C. The baseline
urine sample was collected 15 min before the start of the
study. Total urine (no voiding between collection intervals)
was sampled 2, 4, 6, 8, 12, and 24 h after administration,
followed by sampling once a day (first urine void in the
morning) for the next 10 days. Aliquots of 50 mL of each
void were instantly deep-frozen. Psychotropic and somatic
side effects (sedation, euphoria, anxiety, nausea, vertigo,
headache, irritation of airways, coughing, etc.) were
measured by a visual analog scale (VAS), with 0 cm (0%)
on the 10-cm VAS representing “not at all” and 10 cm
representing (100%) “very strong.” Vital functions (pulse
oximetry, blood pressure, heart rate) were measured by
patient monitors.
Urine samples from athletes
Eighty-one urine specimens from athletes were collected
between 2004 and 2009 in Switzerland and other countries
for doping control purposes in and out of competition. They
tested positive for cannabis (15 ng/mL or more THC-
COOH) and were provided by the Swiss Laboratory for
Doping Analyses in Epalinges.
Analytical assays
THC analysis of clinical test materials
The THC content in cannabis flowers and cannabis
cigarettes before and after smoking was determined by
gas chromatography (GC) with flame-ionization detection
[29].
Plasma analysis
The concentration of total THC, THC-OH, and THC-
COOH (conjugated plus free portion) in plasma was
determined by GC/mass spectrometry (MS) after enzymatic
hydrolysis and automated SPE, following the method of
Feng et al. [30]. In detail, thawed plasma samples were
sonicated for 2 min, centrifuged, and then 30 μL internal
standard solution (containing 0.2 μg/mL THC-d3, THC-
OH-d3, and THC-COOH-d3, each), 2,440 μL 0.1 M
potassium phosphate buffer (pH 6.8), and 200 μL β-
glucuronidase solution (type IX-A from E. coli, 25,000 U/
mL 0.1 M phosphate buffer) were added to 600-μL
aliquots. The mixture was then incubated at 37 °C for
16 h and after cooling 500 μL was transferred to a
preconditioned Bakerbond SPE C18 column by using a
robotic SPE system (Aspec XL, Gilson, Villiers Le Bel,
France). The SPE procedure was as follows: conditioning
with 3 mL methanol twice followed by 3 mL water;
washing with 3 mL water, 3 mL 0.25 M acetic acid, 3 mL
water, and 0.075 mL acetonitrile; elution with 0.5 mL
acetone three times. After evaporation to dryness under
nitrogen (Zymark TurboVap® LV Evaporator, Zymark,
Oftringen, Switzerland) the residue was derivatized with
60 μL BSTFA–TMCS at 70 °C for 30 min.
A 2-μL aliquot was then injected splitless into the GC/
MS system. The Agilent GC/MS system consisted of a GC
6890 N with electronic pressure control, a 7683 autosam-
pler, and a 5975 C mass-selective detector (Agilent,
Waldbronn, Germany). For separation, a DB-5MS capillary
column was used (25 m×0.2-mm inner diameter, 0.33-μm
film; J&W Scientific, supplied by MSP Kofel, Berne,
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Switzerland) with helium as the carrier gas at a constant
flow rate of 1.2 mL/min. The injector, transfer line, and ion
source temperatures were 250, 280, and 230 °C, respec-
tively. The oven temperature was programmed from 150 °C
(0.5 min) to 280 °C at 5 °C/min, and was held at 280 °C for
5 min. The MS system was operated in the selected ion
monitoring mode and the electron multiplier was set at
2,000 eV. The qualifier and quantifier ions (underlined) for
identification were m/z 386, 371, and 303 for THC–
tetramethylsilane (TMS); 474 and 371 for THC-OH-
TMS2; 488, 473, and 371 for THC-COOH-TMS2; 389
and 374 for THC-d3-TMS; 477, 377, and 374 for THC-OH-
d3-TMS2; and 491, 476, and 374 for THC-COOH-d3-
TMS2. Peak assignment was achieved using retention
times, the characteristic ions and ion ratios of the analytes
versus those of control samples. The accepted tolerances
were ±0.1 min and ±15%, respectively.
Calibration was performed by using the internal standard
method and linear regression analysis (least-squares model)
over the concentration range from 0.3 to 75 ng/mL. The
calibrators (N=7) were prepared by spiking pooled blank
plasma with 10 ng/mL internal standard and 0.3–75 ng/mL
nondeuterated standards. The controls (N=5) were prepared
by spiking pooled blank plasma with 10 ng/mL internal
standard and 0.5–50 ng/mL nondeuterated standards.
Triplicates were extracted and analyzed as described above.
Quantitation was based on the target ion ratio of non-
deuterated to deuterated analyte abundance.
Urine analysis
The concentration of total THC, THC-OH, and THC-
COOH in urine was determined by GC/MS after enzymatic
hydrolysis (according to [17]) and automated SPE. In
detail, thawed urine specimens were vortexed and then
60 μL internal standard solution (containing 1.0 μg/mL
THC-d3, THC-OH-d3, and THC-COOH-d3, each), 610 μL
0.1 M potassium phosphate buffer (pH 6.8), and 200 μL β-
glucuronidase solution (50,000 U/mL 0.1 M phosphate
buffer) were added to 2,400-μL aliquots. The mixture was
then incubated at 37 °C for 16 h and after cooling 2,725 μL
was transferred to a preconditioned UCT Clean Screen
CSTHC203 SPE column. The SPE procedure was as
follows: conditioning with 3 mL methanol, 3 mL water,
and 2 mL 0.1 M acetic acid; washing with 2 mL water,
2 mL 0.1 M hydrochloric acid–acetonitrile 70:30 (v/v);
elution with 3 mL 80:20 hexane–ethyl acetate. After
evaporation to dryness under nitrogen the residue was
redissolved in 25 μL acetonitrile and derivatized with
20 μL BSTFA–TMCS at 85 °C for 30 min.
A 2-μL aliquot was then injected splitless into the GC/
MS system. For separation, a DB-35MS capillary column
was used (15 m×0.32-mm inner diameter, 0.2-μm film)
with helium as the carrier gas at a constant flow rate of
2.4 mL/min. The injector and transfer line temperatures
were 250 and 280 °C, respectively. The oven temperature
was programmed from 100 °C (1 min) to 325 °C at 10 °C/
min, and was held at 325 °C for 1 min. The MS system was
operated in the selected ion monitoring mode and the
electron multiplier was set at 2,000 eV (low-range
calibration curve) or 1,200 eV (high-range calibration
curve).
The same ions and parameters were used for peak
assignment and quantitation as for the plasma analysis.
However, owing to the extremely wide concentration
ranges of the urine analytes, two calibration curves (low/
high range) were necessary for THC-OH (0.1–25/25–
250 ng/mL) and THC-COOH (0.1–50/50–1,000 ng/mL) to
stay within the linear range of the calibration graph. Low-
range calibrators (N=9) were prepared by spiking pooled
blank (baseline) urine samples with 25 ng/mL internal
standard, 0.1–25 ng/mLTHC and THC-OH, and 0.1–50 ng/
mL THC-COOH. High-range calibrators (N=8) contained
25 ng/mL internal standard, 25–250 ng/mL THC-OH, and
50–1,000 ng/mL THC-COOH. No high-range calibration
was necessary for THC. THC, THC-OH, and THC-COOH
controls (N=10) were prepared by spiking pooled blank
urine samples with 25 ng/mL internal standard and 0.25–
22.5, 0.25–225, and 0.25–550 ng/mL nondeuterated stand-
ards, respectively. Triplicates were extracted and analyzed
as described above.
Assay validation
Validation of plasma and urine analysis methods was
performed according to the guidelines of ICH [31], the
Society of Toxicological and Forensic Chemistry (GTFCh)
[32] and Peters et al. [33]. Interferences of matrix peaks
with target analytes (selectivity) were checked by pooled
blank plasma and urine as well as baseline specimens of all
12 subjects without adding standards. Control samples (N=
3) were used to determine the lower limit of quantitation
(LLOQ) and the limit of detection (LOD). The LOD was
the lowest concentration at which the signal-to-noise ratio
(S/N, peak height) was 3 or more with acceptable peak
shape and resolution. The LLOQ was the lowest concen-
tration fulfilling the LOD criterion, reaching at S/N 6 or
more the nominal values of the analytes within ±20% and
with a relative standard deviation (RSD) of less than 20%.
Intraday and interday accuracy and precision were deter-
mined at three concentrations. Each level was measured
five times on the same day (intraassay) and on 9 days
(interassay) during 1 month, respectively.
Analyte stability was checked using control samples at
low, medium and high concentrations; the analytes were
reanalyzed after being stored at −20 °C for 30 days and
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were compared with freshly prepared control samples. The
stability in derivatized extracts was similarly checked,
however by comparing them with extracts kept at room
temperature for 36 h. As plasma and urine specimens were
instantly portioned and deep-frozen when collected, freeze–
thaw stability was not determined. Athletes’ urine samples
were stored at −80 °C until analysis. The relative recovery
was determined by using control samples at low and
medium concentrations (0.25–60 ng/mL, N=4) and com-
paring the peak areas with those of the solution of analytes
corresponding to 100% recovery.
Results
Assay validation
Correlation coefficients r2≥0.999 for all analytes indicate
good linearity of the calibration graphs ranging from 0.3 to
75 ng/mL and from 0.1 to 1,000 ng/mL for plasma and
urine, respectively. However, two calibration graphs were
necessary for measuring THC-OH and THC-COOH in
urine. Even in the case of sometimes very concentrated
athletes’ urine samples, no matrix signals interfered with
those of the analytes; thus, the chromatographic system
proved to be selective. With an LLOQ of 1.0 (THC), 0.3
(THC-OH), and 0.75 ng/mL (THC-COOH) in plasma (S/N
10) and 0.1 ng/mL for all analytes in urine (S/N 8) the
assays were sufficiently sensitive. The LOD for both
matrices and all analytes was 0.1 ng/mL (S/N 3). With
intraassay and interassay accuracies of −7 to 10% and −5 to
4% (deviation from target concentration, N=5) for plasma
and −6 to 6% and −5 to 4% for urine, respectively, the
assays were precise. With intraassay and interassay pre-
cisions of 2 to 11% and 3 to 7% (RSD, N=5) for plasma
and 1 to 3% and 1 to 5% for urine, respectively, the assays
were also repeatable and reproducible.
The recoveries (mean ± RSD, N=4) ranged from 61±9
to 76±4% in plasma and from 68±4 to 88±3% in urine,
respectively. The efficiency of the enzymatic conjugate
hydrolysis has been shown by Huestis et al. [17] and
therefore was not tested. When the analytes were stored at
−20°C for 30 days in a matrix, no loss of analytes was
observed. In derivatized extracts the content varied from −3
to 5% and from −7 to 4% when they were kept at ambient
temperature for 36 h and at −20 °C for 1 month,
respectively.
Smoking procedure
The rationale to use cannabis cigarettes with 7% THC was
that the average THC content of marijuana sold in
Switzerland for the last few years was about 11%
(Brenneisen et al., Swiss cannabis profiling study, unpub-
lished data). Although standardized cannabis cigarettes
were smoked following a paced-puffing procedure, the
estimation of the THC dose administered by smoking is a
major variable. Together with the differing efficiency of
inhalation, the losses by side-stream smoke and pyrolysis
are uncontrollable factors [19]. It has been shown that only
20–37% of THC is delivered in the main-stream smoke
[34], with pyrolytic destruction of 23–30% and a side-
stream loss of 6–53% [18, 35]. The pulmonary bioavail-
ability of THC varied between 10 and 50% [15, 18].
In the present study, the mean amount of THC released
by smoking from cigarettes, containing 70 mg THC, was
45±7 mg. Therefore, an average inhaled dose of about
25 mg THC can be estimated, with about 8 mg systemically
available.
Plasma levels
The plasma concentrations of total THC, THC-OH, and
THC-COOH of subjects A–L after a pulmonary dose of
25 mg THC (estimated) are presented in the electronic
supplementary material (Table S1). Figure 1 shows the
plasma profiles of mean total THC with peak plasma
concentrations of 4.2–59.1 ng/mL (20.9±16.9 ng/mL, mean
± standard deviation), occurring at tmax of 5 min. The THC
levels varied between 0.2 and 59.1 ng/mL. THC disap-
peared (levels below the LOD of 0.1 ng/mL) from plasma
within 20 min (subjects B, I), 40 min (subjects A, E, G),
90 min (subjects D, J), and 120–180 min (subjects C, F, H,
L). In subject K, THC was still detectable 360 min after
administration.
Figures 2 and 3 show the plasma profiles of mean total
THC-OH and THC-COOH. With 0.3–3.9 ng/mL (1.8±
1.2 ng/mL), plasma peaks of THC-OH were measured at 5–
20 min. The THC-OH levels varied between 0.1 and
3.9 ng/mL. THC-OH was detectable up to 40 min (subject
A), 120 min (subjects B, J), 180 min (subjects H, I), and
240 min (subjects E, L), whereas the plasma samples of
five subjects (C, D, F, G, K), still contained 0.2 ng/mL or
more at the last two collection time points (360 and
480 min). The THC-COOH plasma peak concentrations
of 3.3–16.4 ng/mL (7.7±4.4 ng/mL) occurred between 20
and 180 min. The THC-COOH levels varied between 0.4
and 16.4 ng/mL. With a mean concentration of 3.7±2.1 ng/
mL, THC-COOH was still present at 480 min in all 12
subjects.
Urine levels
The urine concentrations of total THC, THC-OH, and
THC-COOH of subjects A–L after a pulmonary dose of
25 mg THC (estimated) are presented in the electronic
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supplementary material (Table S2). The renal excretion of
THC started within 2 h after smoking and mostly ended
after 4–6 h, with peak concentrations of 0.2–1.3 ng/mL
(0.7±0.3 ng/mL, mean ± standard deviation) in the
2-h urine void (see also Fig. 4). The THC levels varied
between 0.1 and 1.3 ng/mL. Subject A excreted THC only
in the first void after administration, whereas subject I
excreted THC up to 8 h. The maximum urine levels of
THC-OH were 2.5–14.4 ng/mL (7.1±4.3 ng/mL), in most
subjects measured in the 2-h urine voids too (Fig. 5). The
THC-OH levels varied between 0.1 and 14.4 ng/mL.
Except for subject G, where this metabolite was amazingly
detectable up to 96 h after administration, THC-OH
dropped below the LOD (0.1 ng/mL) after 12–72 h. As
expected, the urinary excretion window for THC-COOH
was broader than that for THC and THC-OH. In most
subjects, THC-COOH could be detected up to 72–96 h after
smoking, with 3.9–38.2 ng/mL (15.3±10.4 ng/mL), peak-
ing at 6–24 h (Fig. 6). The THC-COOH levels varied
between 0.5 and 38.2 ng/mL. Only subject E still had 1.1 ng/
mL in his 120-h urine. Subjects C, D, F, and J showed THC-
COOH urine levels of 15 ng/mL or more (cutoff set by
WADA) up to 24, 12, and 6 h, respectively. All other
subjects did not reach concentrations above the cutoff.
The urine samples (N=81) from athletes who tested
cannabis-positive (15 ng/mL or more THC-COOH) in the
routine doping screening procedure showed THC concen-
trations in the range from 0 to 68.8 ng/mL, with a mean of
2.5±8.2 ng/mL. No THC was detectable in 35% of the
samples. In 22 and 40% of the samples the concentration
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Fig. 1 Plasma levels of total
Δ9-tetrahydrocannabinol (THC;
N=12) after smoking a cannabis
cigarette standardized to 7%
THC. Peak plasma concentra-
tions (Cmax) of 4.2–59.1 ng/mL
(20.9±16.9 ng/mL) occurred at
tmax of 5 min. Minimum detect-
able amounts (greater than or
equal to the limit of detection,
LOD) were measured at 10–
360 min. s.d. standard deviation
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Fig. 2 Plasma levels of total 11-
hydroxy-Δ9-tetrahydrocannabi-
nol (THC-OH; N=12). The
mean Cmax was 1.8±1.2, mea-
sured at tmax of 5–20 min. Min-
imum detectable amounts
(greater than or equal to the
LOD) were reached at 40–
480 min
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ranges were 0.1–1 and 1–10 ng/mL, respectively. THC-OH
ranged from 0 to 2,213.6 ng/mL, with a mean of 51.2±
246.3 ng/mL. No THC-OH was detectable in 2% of the
samples. In 40 and 47% of the samples it ranged from 1 to
10 ng/mL and from 10 ro 100 ng/mL, respectively. THC-
COOH ranged from 1.0 to 9,982.9 ng/mL, with a mean of
245.3±1,111.2 ng/mL. Fifty-two, 28, and 7% of the
samples contained 10–100, 100–500, and more than
500 ng/mL, respectively.
Psychological and somatic side effects
The most observed side effects with high interindividual
variability were sleepiness (18–48±15–33% VAS score,
mean ± standard deviation), euphoria (18–32±23–31%),
dry mouth (3–43±4–32%), and perception alterations
(1–19±1–32%). Mild cardiovascular side effects were
tachycardia and hypotonia.
Discussion
The fully validated GC/MS methods with prior hydrolysis
and automated SPE was shown to be robust, sensitive,
accurate, and reproducible.
To the best of our knowledge, no controlled smoking
study with high-grade cannabis on light cannabis users
measuring THC and metabolites in plasma as well as
monitoring excretion in urine over 11 days has been
performed so far. It was a requirement of the Ethics
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Fig. 3 Plasma levels of total 11-
nor-9-carboxy-Δ9-tetrahydro-
cannabinol (THC-COOH; N=
12). The mean Cmax was 7.7±
4.4 ng/mL (3.3–16.4 ng/mL),
measured at tmax of 20–180 min.
At 480 min THC-COOH was
still present in all subjects. The
concentrations at the last collec-
tion time point were 1.6–7.8
ng/mL
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Fig. 4 Urine levels of total
THC (N=12). The mean Cmax
was 0.7±0.3 ng/mL (0.2–1.3 ng/
mL), measured in the 2-h void.
No more THC was detectable 4–
12 h after administration
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Committee to include only male volunteers in the study,
being cannabis-naïve or infrequent, light users. These
limiting inclusion criteria were not regarded as study
drawback as we hypothesized that top athletes are not
heavy, frequent users and because all Swiss athletes who
have tested cannabis-positive so far have been males
(Antidoping Switzerland, personal communication, 2009).
However, to improve the interpretation of cannabis-positive
doping cases of female athletes, pharmacokinetic data of a
controlled smoking study on female volunteers are needed
too.
To keep the subjects at the CIU for the whole study
period (11 days) was technically not feasible and not
necessary, as the subjects were evaluated very carefully
regarding reliability, thus minimizing the potential risk of
smoking cannabis when not under observation. In addition,
forbidden and uncontrolled cannabis consumption would
have been detected by altered urine excretion profiles, such
as concentration “spikes.”
THC rapidly reached peak levels, which were about
tenfold and threefold higher than those of THC-OH and
THC-COOH, respectively. Huestis et al. [36], who used
cannabis cigarettes standardized to 1.75 or 3.55% THC,
found mean THC plasma peaks 20 and 3 times greater than
those of THC-OH and THC-COOH, respectively. The
mean times to peak concentrations (THC, 8.4 min; THC-
OH, 13.8 min) were rapid as in the present study. However,
the detection times of 7–13 h for THC and 5–11 h for THC-
OH were much longer. The THC plasma peaks are
characterized by very high interindividual variability
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Fig. 5 Urine levels of total
THC-OH (N=12). The mean
Cmax was 7.1±4.3 ng/mL (2.5–
14.4 ng/mL), in nine of 12
subjects measured in the 2-
h urine voids. Except for one
subject, where THC-OH could
be detected up to 96 h after
administration, THC-OH
dropped below the LOD (0.1 ng/
mL) after 12–72 h
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Fig. 6 Urine levels of total
THC-COOH (N=12). The
mean Cmax was 15.3±10.4 ng/
mL (3.9–38.2 ng/mL), mostly
measured after 6–8 h. In nine of
12 subjects, THC-COOH could
be detected up to 72–96 h. One
subject still excreted 1.1 ng/mL
in his 120-h void
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(20.9±16.9 ng/mL at 5 min). It is well known that the
highly variable bioavailability of THC after smoking is
mainly due to individual differences in inhalation techni-
ques and experience [37]. Additionally, in contrast to
experienced users, inexperienced cannabis smokers seem
to titrate their dose to a much smaller amount.
As demonstrated by Huestis et al. [36], the THC-COOH
plasma concentrations peaked later, and showed a long-
lasting plateau and a slow decrease. The urinary peak times
of THC and metabolites were in agreement with those
found in another study, involving smoking cannabis
cigarettes which contained 3.58% THC [20]. The authors
suggested THC levels of more than 2 ng/mL as indicative
for cannabis use within the last 5 h. However, the
observation time was only 8 h (11 days in the present
study); therefore, no comparison of the detection windows
is possible.
Lowe et al. [12] studied chronic, heavy cannabis users
and found THC and THC-OH to be excreted in urine for up
to 24 days. These findings support the hypothesis of Hunt
and Jones [38] that the rate-limiting step in the terminal
elimination of THC is its slow excretion from tissue stores
that may be extended following chronic cannabis use.
Therefore, THC and THC-OH were not regarded as suitable
biomarkers for recent cannabis consumption.
As reported previously [20], THC-COOH showed the
highest intrasubject and intersubject variability (“sawtooth
pattern” [18, 39–41]) and was still detectable after 3 days
(about 4 days after smoking a 3.58% cannabis cigarette
[42]). Thus, the main THC metabolite is not suitable as a
urine marker for recent use. Rather, THC-COOH in urine is
only suggestive of cannabis consumption at some time in
the past [20].
Only four of 12 subjects reached THC-COOH urine
levels above the cutoff level set by WADA (15 ng/mL).
These were measured 6–24 h after administration. Within
8 h, only 0.22±0.16% of the estimated absorbed THC dose
(8 mg) was excreted in the form of THC and metabolites.
The total excretion rate could not be calculated as only the
first morning void was available from study day 2 to study
day 11. Other studies have shown a 20% elimination of the
total dose excreted via urine [38, 43].
It has to be noted that all volunteers underwent an
extensive medical check, stayed healthy for the whole study
period (posttrial check, otherwise excluded), and were told
not to start a diet and not to perform intensive sport
activities. Therefore, these factors cannot be responsible for
the sometimes highly variable plasma and urine profiles
observed. However, as no genotyping was performed,
polymorphisms cannot be excluded.
It is also for the first time that urine samples from
athletes who tested positive for THC-COOH were rean-
alyzed by measuring THC and THC-OH too. Besides high
to very high THC-COOH concentrations, THC and THC-
OH were detectable,in 53 (65%) and 79 (98%), respective-
ly, of the 81 urine samples from athletes. On the basis of the
data of our controlled smoking study and assuming light
cannabis use, we estimate that in these cases consumption
of cannabis took place within 8 to 72 h before urine
sampling. With 68.8 ng/mL THC, 2,213.6 ng/mL THC-OH,
and 9,982.9 ng/mL THC-COOH, one athlete showed
extremely high cannabinoid levels, indicating high-grade
cannabis and/or regular, frequent use.
Conclusions
In addition to the long-lasting THC metabolite THC-
COOH, the parent compound THC and its psychoactive
first metabolite THC-OH should be used as target analytes
for cannabis doping urine analysis. In the case of light
cannabis use this would enhance the chance to detect recent
cannabis consumption potentially influencing the athlete’s
performance in competitions. However, these additional
target analytes do not allow one to discriminate the
intention of cannabis use, that is, for recreational or doping
purposes.
Before cutoff levels for THC and THC-OH can be set,
more cannabis-positive urine samples from athletes have to
be reanalyzed. The results should then be carefully
evaluated also considering the statements made by the
athletes in justification interviews. Another option is to
include blood in cannabis doping analysis. This would
allow a firmer conclusion to be drawn on whether the
subject indeed consumed cannabis shortly before being
tested and experienced pharmacological effects of cannabi-
noids during competition. It can be expected that in the
future some female athletes will also test cannabis-positive.
Therefore, pharmacokinetic data of a clinical smoking
study on female volunteers are needed too.
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